Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 4
2010 4
2011 5
2012 5
2013 10
2014 76
2015 118
2016 109
2017 66
2018 49
2019 15
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

395 results
Results by year
Filters applied: . Clear all
Page 1
Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir.
Ouwerkerk-Mahadevan S, et al. Clin Pharmacokinet 2016 - Review. PMID 26353895 Free PMC article.
Simeprevir is an NS3/4A protease inhibitor approved for the treatment of hepatitis C infection, as a component of combination therapy. ...Clinical studies have shown that simeprevir is a mild inhibitor of CYP1A2 and intestinal CYP3A but does not inhibit hepatic CYP3A. ...
Simeprevir is an NS3/4A protease inhibitor approved for the treatment of hepatitis C infection, as a component of combination therapy
Unexpected Replication Boost by Simeprevir for Simeprevir-Resistant Variants in Genotype 1a Hepatitis C Virus.
Murai K, et al. Antimicrob Agents Chemother 2018. PMID 29661883 Free PMC article.
Simeprevir is a novel NS3/4A protease inhibitor (PI) of hepatitis C virus (HCV). The baseline polymorphism NS3-Q80K is frequently observed in genotype (GT) 1a HCV and often associated with treatment failure in simeprevir-containing regimens. ...The boosted replication of the Q80K+R155K variant by simeprevir could be related to treatment failure in simeprevir-containing antiviral treatments in GT 1a HCV-infected patients with the NS3-Q80K polymorphism. ...
Simeprevir is a novel NS3/4A protease inhibitor (PI) of hepatitis C virus (HCV). The baseline polymorphism NS3-Q80K is frequently obs
Simeprevir and sofosbuvir for treatment of hepatitis C infection.
Chopp S, et al. Am J Health Syst Pharm 2015 - Review. PMID 26294237
SUMMARY: Sofosbuvir and simeprevir are classified as direct-acting agents because they target specific proteins essential to the replication of HCV. ...Both simeprevir and sofosbuvir are approved for the treatment of chronic hepatitis C in combination with other antiviral medications. ...
SUMMARY: Sofosbuvir and simeprevir are classified as direct-acting agents because they target specific proteins essential to the repl …
Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach.
Valade E, et al. AAPS J 2018 - Clinical Trial. PMID 30350297
The pharmacokinetic model adequately describes the time course of plasma concentrations and their variability when simeprevir and/or odalasvir were orally administered. This model can be used as a first step to predict the exposures of concomitant administration of simeprevir and odalasvir in HCV-infected subjects. ...
The pharmacokinetic model adequately describes the time course of plasma concentrations and their variability when simeprevir and/or …
Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
Childs-Kean LM and Hand EO. Clin Ther 2015 - Review. PMID 25601269
We provide a review of the clinical efficacy and safety of sofosbuvir- and simeprevir-containing regimens. METHODS: Studies were identified in PubMed using the terms sofosbuvir and simeprevir in combination with hepatitis C. ...FINDINGS: Simeprevir was studied with peginterferon and ribavirin in 7 published Phase 3 trials, with overall efficacy rates of 59% to 100%. ...
We provide a review of the clinical efficacy and safety of sofosbuvir- and simeprevir-containing regimens. METHODS: Studies were iden …
Simeprevir: a review of its use in patients with chronic hepatitis C virus infection.
Sanford M. Drugs 2015 - Review. PMID 25559421
This article reviews studies relevant to the EU simeprevir label. In proof-of-concept studies, simeprevir had potent antiviral activity against all HCV genotypes, except genotype 3. ...Skin rashes with simeprevir were mostly mild or moderate; serious photosensitivity reactions occur, but are rare. Simeprevir is efficacious and generally well tolerated in patients with chronic HCV genotypes 1 and 4 infection. ...
This article reviews studies relevant to the EU simeprevir label. In proof-of-concept studies, simeprevir had potent antiviral …
Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers.
MacBrayne CE, et al. J Antimicrob Chemother 2018. PMID 29029135 Free PMC article.
OBJECTIVES: To compare dolutegravir and simeprevir pharmacokinetics (PK) when given separately versus in combination. METHODS: Healthy volunteers received: (i) 150 mg of simeprevir once daily for 7 days; (ii) 50 mg of dolutegravir once daily for 7 days; and (iii) 150 mg of simeprevir once daily plus 50 mg of dolutegravir once daily for 7 days, with randomization to treatment sequence. ...Suggesting that simeprevir and dolutegravir can be safely co-administered....
OBJECTIVES: To compare dolutegravir and simeprevir pharmacokinetics (PK) when given separately versus in combination. METHODS: Health …
Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects.
Kakuda TN, et al. Pharmacol Res Perspect 2018 - Clinical Trial. PMID 29736243 Free PMC article.
Simeprevir had no effect on ALS-022227 AUC (0-24 h), whereas odalasvir with/without simeprevir increased ALS-022227 AUC (0-24 h) 1.5-fold. AL-335 had no effect on odalasvir or simeprevir pharmacokinetics. Odalasvir and simeprevir AUC (0-24 h) increased 1.5- to 2-fold for both drugs when coadministered irrespective of AL-335 coadministration. ...
Simeprevir had no effect on ALS-022227 AUC (0-24 h), whereas odalasvir with/without simeprevir increased ALS-022227 AUC (0-24
Simeprevir oxidative degradation product: Molecular modeling, in silico toxicity and resolution by synchronous spectrofluorimetry.
Attia KAM, et al. Luminescence 2018. PMID 29124899
In this article, one of the potential degradation products of the novel antiviral drug simeprevir was isolated and characterized by means of infrared (IR) and mass spectrometry. Moreover, comparative molecular docking, ADMET (absorption, distribution, metabolism, excretion - toxicity) and insilico toxicity prediction studies were applied to evaluate the activity of simeprevir and its degradation product. ...
In this article, one of the potential degradation products of the novel antiviral drug simeprevir was isolated and characterized by m …
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.
Wei L, et al. J Gastroenterol Hepatol 2016 - Clinical Trial. PMID 26777137
Patients received simeprevir 150 mg once daily (QD), simeprevir 100 mg QD, or placebo, in combination with PR for 12 weeks. Patients in the simeprevir groups received PR alone for a further 12 or 36 weeks based on response-guided treatment criteria. ...SVR12 rates were superior for both the simeprevir 100 mg (89%; P = 0.003) and 150 mg (91%; P < 0.001) groups versus placebo (76%). ...
Patients received simeprevir 150 mg once daily (QD), simeprevir 100 mg QD, or placebo, in combination with PR for 12 weeks. Pa …
395 results
Jump to page
Feedback